BOEHRINGER-INGELHEIM
23.5.2019 12:02:07 CEST | Business Wire | Press release
The Angels Initiative announced today at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals across Europe has been achieved.
The Angels Initiative is a unique healthcare approach to improve care for people who have just suffered a stroke (acute stroke care) across Europe and in emerging markets. It is run by Boehringer Ingelheim in partnership with the European Stroke Organisation (ESO), the World Stroke Organisation (WSO), the Stroke Alliance for Europe (SAFE) and many other national stroke societies and companies.
“Stroke is one of the leading causes of disability and death. And when a stroke strikes, every second counts to deliver optimised care as fast as possible to preserve life and minimise disability,” commented Prof. Valeria Caso, past president of the ESO. “There is a need to vastly improve the quality and speed of stroke care in Europe. I’m delighted that through the Angels Initiative, we are collectively making a real change, having already established thousands of participating clinics, and the work will keep going.”
If stroke patients are treated as quickly as possible and according to best standard of care in dedicated stroke centres, their chances of survival and a disability-free life can be improved dramatically.
The Angels Initiative aims to improve stroke care by building acute stroke networks, optimising treatment processes and sharing knowledge to set-up specialised stroke-units. The common goal is to improve care for as many people as possible who have suffered a stroke and thus save lives. Started in 2016, the Angels Initiative has now established a community of more than 2,700 stroke-centres and stroke ready hospitals in 95 countries worldwide including 37 European countries.
“This is a huge achievement for the Angels Initiative in a very short period of time. At Boehringer Ingelheim we are proud to be part of this driving force, making a change for thousands of patients,” commented Thomas Fischer, Global Head of the Angels Initiative at Boehringer Ingelheim. “We have completed training in clinics in 37 European countries, but our work does not stop here. We will continue to upskill and support new fully-functional stroke-units in Europe and emerging markets.”
As an ongoing commitment to the community, the Angels Initiative and ESO recognise clinics that are helping to drive the change for better, faster stroke care, through the ESO Angels Awards. During an award ceremony at ESOC today, 331 clinics across Europe have been recognised with ESO Angels Awards for leading the way through fully-optimised stroke care.
About the Angels Initiative
Suffering a stroke is one of the
most devastating medical emergencies that can happen to a person.
Fifteen million people worldwide suffer a stroke every year; one-third
of these people die as a consequence; another third are left permanently
disabled.1,2
Guidelines recommend that patients who have had
a stroke are treated in a specialised stroke unit by a dedicated team.
In turn, treatment should be initiated as quickly as possible after
onset of symptoms3,4
but this does not always happen.
A dedicated team of Angels consultants provide doctors, nurses and ambulance crews with the training and support they need to create and improve the treatment pathways and processes around stroke care. The Angels consultants run assessments together with the hospitals; compare existing processes with guidelines; provide training and ongoing support for the hospital staff as well as process- and quality-monitoring. Examples of these measures include checklists, which help to standardise processes and to limit unnecessary delays. In addition, the Angels Initiative offers educational tools and programmes – digital as well as analogue, support for pre- and in-hospital process optimisation and a community platform for peer-to-peer exchange and access to the world’s leading stroke specialists.
For further information on the Angels Initiative, visit: https://www.angels-initiative.com/
Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/network-1500-stroke-ready-clinics-across-europe
Intended audiences:
This press release is issued from our
Corporate Headquarters in Ingelheim, Germany and is intended to provide
information about our global business. It is directed to the
international audience outside Germany. Please be aware that information
relating to the approval status and labels of approved products may vary
from country to country, and a country-specific press release on this
topic may have been issued in the countries where we do business.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005260/en/
Contact:
Media Contact Boehringer Ingelheim Corporate Communications Media + PR Eva Maria Schwenk 55216 Ingelheim/Germany Tel: +49 (6132) 77-98192 Fax: +49 (6132) 72-98192 Email: press@boehringer-ingelheim.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
